

# Lay writing: Strategies for improving assent forms for children and adolescent participation in health research

Danielle Yuill<sup>1</sup>, Rachel Barron<sup>1</sup>, and Jennifer Preston<sup>2</sup>

1 GW Research Ltd, Cambridge, UK

2 NIHR Alder Hey Clinical Research Facility, Liverpool, UK

## Correspondence to:

Danielle Yuill  
Technical Writer  
GW Research Ltd  
Sovereign House  
Vision Park  
Histon  
Cambridge, UK CB24 9BZ  
+44 (0) 1223 266800  
dyuill@gwpharm.com

## Abstract

Writing for lay audiences is recognised as a difficult task for medical writers, whose specialised knowledge can often hinder effective lay communication. This task is even more challenging when preparing clinical trial information for a paediatric population. Involving advisory groups in the development of clinical trial materials improves their quality and ensures that they are fit for purpose. This article describes how medical writers can build successful partnerships with advisory groups in developing assent forms for children being approached to participate in clinical trials.

Research involving children has more complex considerations than research with adults. Although children are dependent on their parent(s)/legal guardian to provide written informed consent for their participation in clinical trials, they should be involved in the decision-making

process if they have the capacity to assent.<sup>1–4</sup> Assent is, therefore, given by children with capacity, in addition to consent by the legal representative(s), and indicates their understanding of the trial procedures and willingness to participate.<sup>2</sup> In the European Union, while there is consensus regarding the need for assent forms to be adapted in accordance with the age and level of understanding of the children targeted for inclusion, there is discordance regarding the appropriate age of assent and the requirement of a child's signature to confirm their agreement to participate.<sup>5</sup> A medical writer tasked with developing assent form templates for use across multiple countries and multiple trials is, therefore, presented with challenges in negotiating national laws and local practices, as well as trying to ensure the use of appropriate language to aid a child's understanding of a clinical trial.

We advocate partnering with children's advisory groups to overcome some of the challenges of writing for paediatric populations; such partnering is a concept that is newly

emerging in the pharmaceutical industry and often daunting for medical writers to undertake. This article describes the process of assessing the suitability of assent forms and how the support of advisory groups can aid medical writers in preparing clinical trial materials that are fit for purpose.

## Where to start

As medical writers, how do we write assent forms to adequately inform children of differing levels of maturity about participation in clinical trials? How do we know that what we produce provides adequate information to enable a child to make a choice? The internet is an abundant source of information, and there are several examples of ethically approved informed assent forms, which medical writers could use to develop their own company-specific templates. Most of these examples, however, are outdated and do not describe the involvement of children and young people in their development.

We aimed to develop two new assent form templates for use in our paediatric clinical trials that provide sufficient information for children and young people to make informed decisions about participation.

Our original assent form templates (categorised as being suitable for younger children and older children) had been developed in 2013 when we conducted our first clinical trial in paediatric patients. On review in 2016, we determined that there was scope to improve the design and overall comprehensibility of the templates.

Having prior experience with lay writing and the involvement of patient and public groups

An important element of involving lay groups in clinical research is acknowledging the value of the reviewers' input.





Figure 2. Completed YPAG review form based on assessment of assent for younger children

during which the overall comprehension of the templates was assessed, including design, format, clarity, and readability. Although all reviewers felt

that the information presented in both assent forms was sufficiently *lay* for children and young people to understand, drastic improvements to the designs were suggested by the reviewers to aid overall comprehension and make them more user-friendly. We had detailed discussions with the children and young people on how to achieve this.

### Acting on advice

For younger children, the YPAG suggested “cute animals instead of people” to make the information more reader-friendly (Figure 2). As adults with several years of experience in clinical research, we initially felt that this would be suggestive of animal testing. However, on discussing these concerns with the group, they explained how younger children would not necessarily be aware of animal testing. For older children, the YPAG thought that the “layout [was] confusing with arrows” and suggested a design based on colourful sticky notes and stickers pinned to a notice board.

During our meeting, the group raised an issue regarding the need for a child’s signature on the assent form, as per the International Conference on Harmonisation E11 guidelines (clinical investigation of medicinal products in the

paediatric population).<sup>2</sup> On both assent forms, our initial design used a traditional consent form template with the ethical elements for signature tailored for assent (e.g., “I understand I can stop the study at any time”). For older children, the YPAG altered some of the wording on the signature page to ensure it was understandable. For younger children, however, the YPAG was concerned that they would be unable to understand the elements of assent and provide a signature. To overcome this issue, the group suggested the use of a happy face with a corresponding tick box to acknowledge assent, and a sad face to acknowledge dissent.

### Acknowledging advice

An important element of involving lay groups in clinical research is acknowledging the value of a reviewer’s input.<sup>9,10</sup> Once we had completed the redesign of both assent form templates, we sent a copy of these to the YPAG to show the young people who took part in the review process how we had incorporated their ideas and suggestions (Figure 3).

### Conclusion

The input of children and young people highlighted the value of involving YPAGs or similar groups in clinical trial design and

Figure 3. Assent form templates post-YPAG review

development. Although the initial feedback gave testament to our ability to write for lay audiences, and indeed the Flesch-Kincaid scores of our revised templates were aligned with this finding, the overall design of the draft templates affected their suitability. As such, had we not involved the YPAG, although it could be assumed that younger and older children would be able to understand our clinical trials, it is plausible that they would not have engaged with the material, resulting in dissent or potentially subsequent withdrawal post-enrolment.

It should be recognised that there is not necessarily a one-size-fits-all model of assent, as a child's level of understanding will differ on an individual basis. While it is possible to create templates to aid the development of trial-specific assent forms, the decision regarding the suitability of clinical trial materials is ultimately in the hands of the ethics committees from whom approval is being sought. As such, adaptations should be made to templates based on feedback from ethics committees and evidence-based learning and research.

Although writing for children and young people can be difficult, and involving advisory groups can be daunting, medical writers should not be discouraged from pursuing this important area of work. The involvement of advisory groups benefits the paediatric clinical trial process through an improved understanding of clinical trial materials by potential participants and can, in turn, improve medical writers' lay writing skills.

## Acknowledgements

The authors would like to thank all the young people at Liverpool YPAG for their continued support in improving the information that we provide for children and young people taking part in clinical trials.

## Conflicts of interest

The authors declare no conflicts of interest.

## References

1. World Medical Association Declaration of Helsinki. JAMA. 2013;310(20):2191–4.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Clinical Investigation of Medicinal Products in the



- Pediatric Population (E11). 2000.
3. US Department of Health and Human Services. Code of Federal Regulations, Title 21 (Food and Drugs) Food and Drug Administration, Part 46 – Protection of Human Subjects, Subpart D, Section 46.408. Accessed 26 July 2016.
4. Giesbertz N, Bredenoord A, van Delden J. Clarifying assent in pediatric research. Eur J Hum Genet. 2013;22(2):266–9.
5. Lepola P, Needham A, Mendum J, Sallabank P, Neubauer D, de Wildt S. Informed consent for paediatric clinical trials in Europe: Table 1. Arch Dis Child. 2016;101(11):1017–25.
6. Calderón JL, Morales LS, Liu H, Hays RD. Variation in the readability of items within surveys. Am J Med Qual. 2006;21(1):49–56.
7. National Institute of Adult Continuing Education. Readability: how to produce clear written materials for a range of readers. Leicester: NIACE; 2009.
8. National Institute for Health Research. Medicines for Children Research Network. Guidance document for researchers designing patient information leaflets. Available at: <http://www.hra-decisiontools.org.uk/consent/docs/MRCNYPAG-Guidance-for-Researchers-designing-Patient-Information-Leaflets.pdf>.
9. INVOLVE. Involving children and young people in research: top tips for researchers. Eastleigh: INVOLVE; 2016.
10. INVOLVE. Briefing notes for researchers: involving the public in NHS, public health and social care research. Eastleigh: INVOLVE; 2012.

## Author information

**Danielle Yuill** is a technical writer at GW Pharmaceuticals. She has a Master of Research degree in clinical research and experience involving patients and members of the public in the development of clinical trials. She has extensive experience writing and designing clinical trial materials for lay audiences.

**Rachel Barron** is a senior medical writer at GW Pharmaceuticals with an interest in writing for lay audiences. She is a qualified vet who transitioned to medical writing 12 years ago. As such, she has considerable previous experience of communicating medical information to lay audiences (pet owners!).

**Jennifer Preston** is the Patient and Public Involvement (PPI) Manager for the NIHR Alder Hey Clinical Research Facility and PPI Priority Lead for the NIHR Clinical Research Network Coordinating Centre. She set up the first YPAG in Liverpool in 2006, followed by groups throughout the UK, Europe, and the US.